Methods:  Rats underwent splenic artery ligation by occluding the main splenic artery. Two days later, the total hepatic ischemia (Pringle Selleckchem GSI-IX maneuver) was conducted, and then a two-thirds partial hepatectomy (PH) was performed just before the start of reperfusion. HO inhibitor was twice injected s.c. at 3 and 16 h before the Pringle maneuver. HO-1 levels were determined by western blotting. Liver injury was biochemically assessed. Results:  In normal rats, HO-1 was highly expressed in the spleen, but not in the liver. Splenic artery ligation induced HO-1 in the livers. When rats underwent 20 and 30 min of Pringle maneuver/PH,

survival rates were 28% and 8%, respectively. Splenic artery ligation significantly improved both the survival rates: 73% and 56%, respectively. Under these conditions, administration of HO-1 inhibitor at least partly negated the efficacy of splenic artery ligation. Splenic artery ligation also increased the recovery rate of the remnant liver mass and platelet counts in Pringle maneuver/PH-treated rats. Conclusion:  Splenic artery ligation was significantly effective on the hepatic

I/R injury in partially hepatectomized rats. Induction of HO-1 may be at least partly involved in the improvement of this injury. “
“Background: Acute-on-chronic liver failure (ACLF) is defined differently between Eastern (APASL) and Western countries (EASL-CLIF). This study aimed to investigate the prevalence find more of ACLF according to the APASL vs. EASL-CLIF definitions as well as short-term mortality and associated factors in patients with acute decompensation (AD). Methods: We collected 上海皓元医药股份有限公司 data for 1022 hospitalized patients (male 756, median age 55±12 years) with chronic liver disease (CLD) and AD from January 2013 to December 2013 from 16 academic hospitals in Korea. The Kaplan-Meier method with log-rank test

was used to calculate short term mortality (28-day and 90-day). Results: The most common underlying cause of CLD was alcohol (63.3%) and the main forms of AD were variceal bleeding (29.2%), more than one events (20.3%), and ascites (17.2%). The prevalence of ACLF development based on the APASL and EASL-CLIF definitions were 158 (15.5%) and 132 (12.9%) at admission, and 69 (6.8%) and 41 (4.0%) within 28 days of enrollment, respectively. The 28-day and 90-day mortality were higher in patients with ACLF at enrollment than in those without ACLF at enrollment (by APASL definition: 18.4% vs. 4.6%, and 29.5% vs. 8.6%, respectively, P < 0.001; by EASL-CLIF definition: 27.3% vs. 3.7%, and 41.7% vs. 7.8%, respectively, P < 0.001). At the time of admission, of the 242 patients who satisfied the APASL or EASL-CLIF definition, only 48 (19.8%) patients satisfied both definitions, while the remaining patients (81.2%) satisfied only one (with APASL definition, 110 patients; with EASL-CLIF definition, 84 patients).